Evidence mapPaperPMID 36530444Full record

SynthesisFrontiers in cellular and infection microbiology2022

Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes: A systematic review.

Shuo Zhang, Feiying Deng, Jingxian Chen, Fengwu Chen, Zezhen Wu, Liping Li, Kaijian Hou

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Frontiers in cellular and infection microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. T-Cell Receptor Sequences Identify Combined Coxsackievirus-International journal of molecular sciences · 2024
    Article
  10. Review
  11. Advances in fecal microbiota transplantation for the treatment of diabetes mellitus.Frontiers in cellular and infection microbiology · 2024
    Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Shuo ZhangShantou University Medical College, Shantou, China.
Feiying DengShantou University Medical College, Shantou, China.
Jingxian ChenDepartment of Endocrine and Metabolic Diseases, Longhu People's Hospital, Shantou, China.
Fengwu ChenDepartment of Endocrine and Metabolic Diseases, The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
Zezhen WuShantou University Medical College, Shantou, China.
Liping LiSchool of Public Health, Shantou University, Shantou, China.
Kaijian HouDepartment of Endocrine and Metabolic Diseases, Longhu People's Hospital, Shantou, China.
First Affiliated Hospital of Shantou University Medical College · CNShantou University · CNShantou University Medical College · CNYue Bei People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There is a strong link between fecal microbiota and the development of type 1 diabetes. As an emerging therapeutic modality, fecal microbiota transplantation has been shown to be safe and effective in the treatment of many intestinal and extraintestinal diseases. Various studies have found that fecal microbiota transplantation can treat diseases by correcting patients' immune disorders. Besides, many studies have found that fecal microbiota transplantation can improve glycemic control and insulin resistance in diabetic patients. Therefore, this paper reviews the mechanism of action of fecal microbiota transplantation on autoimmune-mediated T1DM and the current research progress, feasibility, and issues that need to be addressed in the future development of fecal microbiota transplantation in the treatment of autoimmune-mediated T1DM.

Indexed as

Diabetes Mellitus, Type 1Gastrointestinal MicrobiomeFecal Microbiota TransplantationFecesHumansIntestinesAutoimmune-mediated type 1 diabeteschronic inflammatory statefecal microbiota transplantationgut microbiotainsulin resistance

Identifiers

PMID36530444
PMCPMC9751335
OpenAlexW4310482331

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.